Determination of carcinogenic arylamine N-oxidation phenotype in humans by analysis of caffeine urinary metabolites.
Kadlubar
F F
FF
National Center for Toxicological Research, Jefferson, AR 72079.
Talaska
G
G
Butler
M A
MA
Teitel
C H
CH
Massengill
J P
JP
Lang
N P
NP
D000107:Acetylation; D001191:Arylamine N-Acetyltransferase / Q000235:genetics / Q000378:metabolism; D001711:Biotransformation; D002110:Caffeine / Q000378:metabolism*; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics / Q000378:metabolism*; D004198:Disease Susceptibility; D006801:Humans; D007527:Isoenzymes / Q000235:genetics / Q000378:metabolism*; D010084:Oxidation-Reduction; D010641:Phenotype; D013806:Theophylline / Q000652:urine*; D014498:Uracil / Q000031:analogs & derivatives / Q000652:urine; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced / Q000235:genetics; D014970:Xanthines / Q000652:urine
D007527:Isoenzymes; D014970:Xanthines; D002110:Caffeine; D014498:Uracil; C053085:1-methylxanthine; C036692:5-acetylamino-6-formylamino-3-methyluracil; D003577:Cytochrome P-450 Enzyme System; D013806:Theophylline; D001191:Arylamine N-Acetyltransferase; C021183:1,7-dimethylxanthine